CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 350 enrolled
Drug / intervention
JUUL +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03502200
NCT03502200N/ACompleted

Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failure

Ohio State University Comprehensive Cancer Center·interventional·Posted Apr 18, 2018·Updated Jul 21, 2023

In Brief

A clinical study evaluating JUUL and Treatment As Usual for Smoking, Cigarette. Completed, enrolled 350 participants across 1 site.

Detailed Summary

The overall aim of the study is to evaluate the provision of e-cigarette (EC) versus NRT on smoking behavior, product use patterns and continued use, and iCO, a biomarker of toxicant exposure, among a sample of recent QL treatment failures. We will randomly assign N=372 smokers (targeted accrual) to EC (n=186) or QL treatment as usual with combination nicotine replacement therapy (NRT; n=186). All participants will receive three calls from QL coaches and EC and NRT will be provided at no cost for 8 weeks. The final follow-up will occur 12-weeks post baseline.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedApr 18, 2018
Enrollment StartOct 15, 2020
Primary CompletionJan 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.2 years ago

Interventions

JUULdevice

Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.

Treatment As Usualother

Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.